Corvus Pharmaceuticals, Inc. (CRVS)
Corvus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing targeted therapies for cancer and immuno-oncology. Founded in 2014 and based in Burlingame, California, the company concentrates on designing small molecule drugs intended to modulate the immune system to improve cancer treatment outcomes.
Company News
Corvus Pharmaceuticals presented interim data from a Phase 1b/2 clinical trial of ciforadenant for metastatic renal cell cancer, showing promising results when combined with ipilimumab and nivolumab, with a 34% deep response rate and favorable safety profile.
U.S. stock futures climbed on Wednesday as investors await the Federal Reserve's interest rate decision and economic data releases. The Dow Jones index extended its losing streak to nine consecutive sessions, the longest since 1978.
The heavy selling pressure might have exhausted for Corvus (CRVS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Discover rare investment picks for December 2023 that you might have overlooked from analysts who make less-frequent recommendations. Read more here.
Penny stocks typically trade for less than $5 and generally belong to… The post 3 Hot Penny Stocks To Watch Before Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.